Clarity Pharmaceuticals
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4 Cornwallis Street National Innovation ...Phone Number
+61 292094037Revenue
<$5 MillionIndustry
About Clarity Pharmaceuticals
Clarity Pharmaceuticals Org Chart
Is Clarity Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Clarity Pharmaceuticals is spiking on competitors!
Click to see if Clarity Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Clarity Pharmaceuticals launches new products
Check if Clarity Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Clarity Pharmaceuticals has new funding data
Earning: See what the market has to say on Clarity Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Clarity Pharmaceuticals
Website visits: Recent activity has been detected on your website
Clarity Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Clarity Pharmaceuticals
Compare insights from companies similar to Clarity Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Clarity Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Clarity Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Clarity Pharmaceuticals.
Clarity Pharmaceuticals financials insights
Gather financial insights about Clarity Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Grant
$306K
Unspecified
$1M
Unspecified
$1.4M
Grant
$2.5M
Unspecified
$25M
Other Financing Round
$121M
Clarity Pharmaceuticals Tech Stack
A closer look at the technologies used by Clarity Pharmaceuticals
Most Recent Scoops
Clarity Pharmaceuticals News & Media
Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for 64Cu-SAR-bisPSMA with Nucleus RadioPharma, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to tCo-PSMA data published in the European Urology journal
SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results from the Co-PSMA (NCT06907641)[1] investigator-initiated trial (IIT) are now published in European Urology[2], the official journal of the European Association of Urology (EAU) Congress 2026 with an impressClarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics
SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing...Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
HIGHLIGHTS Oral presentation on key results from the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) was delivered by Prof Louise Emmett (St Vincent's Hospital Sydney) at the European Association of Urology (EAU) Congress 2026 on the 16th of March 2026 in London, UK[2]....
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Clarity Pharmaceuticals
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on developing next-generation theranostic products to enhance treatment outcomes for cancer patients. Utilizing their proprietary SAR Technology, they create highly targeted radiopharmaceuticals for both diagnosis and treatment, particularly in significant cancer indica... Read More

